# Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Source: https://onco.cc/trials/nct05671822/  
OnCo record `nct05671822` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab rezetecan, Retlirafusp alfa, Capecitabine, Adebrelimab and Oxaliplatin in gastric & gastro-oesophageal junction cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer is a phase 2 interventional study registered as NCT05671822 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 258 participants planned, started 2023-03-14 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine, SHR-A1811, SHR-1316, and capecitabine, SHR-A1811, SHR-1316, capecitabine,and oxaliplatin and SHR-A1811, SHR-1316, and 5-FU.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05671822
- Phase: 2
- Setting: A Phase Ib/II Study of SHR-A1811 Combinations in Patients With Advanced/Metastatic HER2 Expression Gastric /Gastroesophageal Junction Adenocarcinoma
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 258

## Sources

- ClinicalTrials.gov NCT05671822: https://clinicaltrials.gov/study/NCT05671822

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Retlirafusp alfa](https://onco.cc/drugs/retlirafusp-alfa/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct05671822.json